(VIANEWS) – The NYSE ended the session with Teva Pharmaceutical (TEVA) jumping 11.34% to $9.23 on Wednesday while NYSE dropped 1.05% to $16,184.91.
Teva Pharmaceutical’s last close was $8.29, 27.6% below its 52-week high of $11.45.
About Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Earnings Per Share
As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-1.42.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.93%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 23.5% and positive 5.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Teva Pharmaceutical’s EBITDA is 93.61.
Sales Growth
Teva Pharmaceutical’s sales growth is negative 2% for the ongoing quarter and negative 2.9% for the next.
More news about Teva Pharmaceutical (TEVA).
